Possible Thrombosis Threats In Chronic Medical Conditions Is Contributing The Global Anti-thrombotic Drugs Market To Grow At 6.61% Of CAGR By 2027.

Triton Market Research presents their Global Anti-Thrombotic Drugs Market report segmented on the basis of antiplatelets, anti-coagulants, thrombin inhibitors and by geographical region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - discussing Industry Value Chain Analysis, Porter's 5 Force Analysis, Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2019-2027).

Antithrombotic drugs are therapeutically used to prevent blood clots. Triton Market Research expects the global Anti-thrombotic drugs market to witness a compound annual growth rate of 6.61% during the forecasted period 2019-2027. Anti-platelets work in the same line by restricting the aggregation or migration of blood platelets. The healthcare industry has developed a better understanding of the molecular mechanisms of blood clotting, such as underlying thrombogenesis, advances in recombinant DNA technology, improvements in drug designing, and increased understanding of antithrombotic proteins. As a result, governments across the world have started taking initiatives and implementing appropriate healthcare policies for preventing blood clot during medical procedures such as knee and hip replacement surgeries. This significantly boosts the global market for Antithrombotic drugs. Moreover, the limitations of existing antithrombotic/anticoagulant drugs provide opportunities for new products to enter the market and command a sizable market share

Low molecular weight heparin and oral anticoagulants (vitamin K antagonists) are the popular drug types in this market. The anti-coagulants market is also categorized by the rapid onset anticoagulant (ROA) segment which is sub-divided into oral and injectable.  Anticoagulant drugs are being used in the aftercare for various medical conditions like hip/ knee replacement, cardiovascular disorders, kidney disorders, and strokes. These diseases are often associated with thrombosis, wherein blood forms clots. This can lead to an embolus, where the clot can break free and travel through the blood vessels, obstructing the normal blood flow which can prove fatal for the patient’s life. To avoid this, anticoagulants/antithrombotics are prescribed by doctors.

The biggest market for anti-thrombotic drugs was in North America by the year 2018. According to the CDC 2015 report, approximately 60,000-100,000 individuals in the US die from deep vein thrombosis or pulmonary embolism, both associated with blood clotting. Warfarin is the most commonly prescribed oral anticoagulant in this region. The European market is also showing a steady growth, owing to the high medical R&D in the region. However, the region that holds the highest potential for the market globally is the Asia-Pacific. APAC offers a large patient pool and developing economies that are dedicatedly working on improving their healthcare sector.

Mergers and acquisitions (M&A) lead the industry toward further consolidation leading to broader geographical footprint and wider customer base. Hence, it is no surprise that it is the most preferred strategy adopted by market bigwigs in the global anti-thrombotic drugs market. In this report, Triton Market Research has profiled some of the key market companies like Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Armetheon Inc., Abbott Laboratories, Bayer, CSL Behring, Bristol –Myers Squibb Co. and Baxter International.